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 Pharmaceutical drug products contain various excipients in combination with the active 
pharmaceutical ingredient (API), and those excipients have the potential to have as impurities 
reactive oxygen species that can react directly with the API and lead to oxidative degradation.  
Such degradation can impact long-term stability of the drug product, reduce drug product purity, 
limit shelf life, and increase time to market.  Peroxy compounds are a common class of such 
reactive impurities, but there is an absence in the literature of a method for detection of total 
peroxide level in pharmaceutical excipients when the identity of the peroxy contaminant is not 
known.  In this thesis, novel modifications were made to the 1966 ASTM E 299-08 method for 
enhanced and robust detection of active oxygen in pharmaceutical excipients.  The modified 
ASTM E 299-08 method was evaluated using spiked solutions of hydrogen peroxide, a 
hydroperoxide compound, and a peroxide compound.  Liquid and solid excipients were then 
evaluated for active oxygen levels to demonstrate the utility and breadth of the modified method 
to cover a wide range of excipients.  The polyethylene glycol (PEG) class of compounds was 
chosen for more in-depth evaluation due to their susceptibility to autoxidation and the existence 
of various molecular weight grades of PEG compounds.  PEG 1000 was chosen along with 
lestaurtinib (CEP-701) to prepare a novel drug product, which was evaluated on stability for 
active oxygen and assay impurity levels.  The results showed that the modified ASTM E 299-08 
method successfully quantified both the total active oxygen levels and the CEP-701 peroxy 
impurity levels, which agreed with those obtained by an HPLC assay method.  The modified 
ASTM E 299-08 method has important applicability in the pharmaceutical industry as a method 
that can be used for preliminary screening of excipients and new formulations to predict potential 
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CHAPTER 1.  Introduction 
 
Purpose of the Research Performed 
The purpose of the research described in this thesis was to develop a sensitive, versatile, 
reliable, and reproducible method for rapid quantification of trace levels of active oxygen species 
in pharmaceutical excipients and a model drug product when the identity of the peroxy moiety 
was either known or unknown. 
 
1.1.  Pharmaceutical Importance of Excipient Impurities 
Pharmaceutical drug products contain various excipients in combination with the active 
pharmaceutical ingredient (API), and those excipients have the potential to have as impurities 
reactive oxygen species that can react with the API and lead to oxidative degradation.
1
  
Excipients have been found to contain trace amounts of reactive impurities including metal ions, 
peroxides, low-molecular weight aldehydes, and organic acids.
2
  Understanding the impurity 
profiles of excipients has increased in importance because excipient impurities such as 
peroxides, even in trace levels, not only have the ability to catalyze API-excipient reactions, but 
can also catalyze excipient-excipient or impurity-impurity reactions, which can further contribute 
to the instability of a drug product.
3,4,5
  Oxidative degradation of the API can significantly impact 
the long-term stability of the drug product, which can reduce drug product purity, prolong 
formulation development, limit shelf life, and increase time to market.
5
        
 Quantifying the level of peroxides in an excipient before selection for formulation 
development is especially important when the API is known to be susceptible to oxidative 
degradation.  Screening excipients for peroxide levels prior to use in a formulation is imperative 





Being proactive in characterizing reactive oxygen impurities during excipient selection can  
enhance the probability of API-excipient compatibility, including evaluation upfront whether the 
inclusion of an antioxidant will be required, saving valuable development time.
1 
  However, the 
identity of the reactive oxygen species in the pharmaceutical excipient may not be known, which 
makes quantification of the levels in an excipient very difficult, but nonetheless important to 
predicting the possible reactions that can occur between the excipient impurities and the API.
3 
 
There is limited literature addressing this point and a need exists for a method that can detect the 
total active oxygen level in a pharmaceutical excipient when the identity and structure of such 
species are not known. 
 
1.2.  Comparison of the ASTM E 299-08 Method to Competing Methods 
Previously published techniques in the literature evaluated hydrogen peroxide (H2O2) 
levels in excipients using a liquid chromatographic method combined with coulometric 
electrochemical detection (LC-CECD), a liquid chromatographic system with a dual channel 
amperometric-electrochemical detector (LCEC), and a flow injection (FI) method.
4,6,7
  Other 
techniques evaluated total hydroperoxide content in excipients using version two of the ferrous 
oxidation-xylenol orange assay method (FOX2) with ultraviolet (UV) detection.
5,8,9,10,11
    
Ferrous ion methods have been employed to measure peroxide levels, but reviews of the methods 
in literature have summarized them as less accurate than iodometric methods because they 
produced 2 to 5 times higher peroxide levels when compared to the same sample measured 
iodometrically, a well-defined system matrix is needed, and exposure to air must be 
avoided.
8,12,13 
  Colorimetric procedures for detection of organic peroxides are also described in 
the literature, but there are disadvantages within the methods.
14,15
  Colorimetric methods  have 
3 
 
limited applicability and the utilization of a volumetric procedure does not allow for detection of 
low peroxide levels, due to high blank values.
14,15,16 
  In addition, the previous techniques are 
specific to a known peroxide,  measure peroxide levels indirectly, sacrifice sensitivity, include 
many procedural steps, and are time-consuming.
4,5,6
  The American Society for Testing and 
Materials (ASTM) E 299-08 standard test method was chosen as the basis for the method in this 
thesis.
17
  The ASTM E 299-08 method is an iodometric method that utilizes spectrophotometric 




1.3.  The Modified ASTM E 299-08 Method 
A spectrophotometric test method for peroxide quantification, in terms of active oxygen, 
was developed that utilizes and expands upon the knowledge gained from the ASTM E 299-08 
method and iodine redox chemistry.
17,7
  Iodometric methods in the literature used acetic acid in 
the acid solution in order to serve as a medium for the reduction of peroxides by iodide ions.
13,18
  
The reaction taking place was the reduction of an active oxygen species by the iodide ion, which 
causes the release of iodine, which can be measured by a spectrophotometer.
18,19
  The overall 
reaction utilized in this method is described below: 
ROOR' + 2 KI + 2 CH3CO2H  I2 + 2 CH3CO2K + ROH + R'OH 




The modified method for active oxygen analysis was developed and included procedural 
improvements to the ASTM E 299-08 method, which was originally approved in 1966, required 
multiple procedural steps, utilized a custom glass reaction absorption cell for detection of trace 
active oxygen levels, and specifically focused on active oxygen in organic solvents.
17
 The 
improvements to the ASTM E 299-08 method were developed in order to allow the method to be 
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more robust, convenient, and flexible.  The modified ASTM E 299-08 method reduced the 
number of steps in the ASTM E 299-08 method and eliminated the need for the special 
absorption cell without sacrificing the sensitivity and reproducibility of the method.  It
 
utilizes 
iodine standard calibration curves that cover a more specific and lower magnitude range of active 
oxygen levels, and quantifies the amount of active oxygen (ppm) present in H2O2-spiked samples 
accurately.
6,4,7,8,17
 The expanded method focuses on rapidly quantifying trace levels of active 
oxygen in both liquid and solid pharmaceutical excipient lots from different vendors and relates 
the findings to various classes of excipients.
21,6
   
 
1.4.  Pharmaceutical Application of the Modified ASTM E 299-08 Method 
Hydroperoxide compounds are common intermediates in the degradation of fats, oils, and 
polymers, which are frequently used excipients in pharmaceutical formulations.
22,23
  
Hydroperoxides are the primary products of autoxidation and thermal oxidation in formulations, 
which decompose to secondary oxidation products consisting of aldehydes, ketones, alcohols, 
hydrocarbons, volatile organic acids, and epoxy compounds.
24
   Analytical methods in the 
literature can either determine the total amount of hydroperoxides through primary oxidation 
products or can determine the amount of hydroperoxide by quantifying the formation of the 
decomposition products.
22
  The negative commonalities between the existing methods are that 
the peroxide produced must be known, derivatization is used, and chromatographically only the 
secondary products are quantified.
22,23,24
  The modified ASTM E 299-08 method was employed 
to show it’s utility to detect both total active oxygen and specific hydroperoxide levels 
concurrently in a formulation without the downfalls of the existing methods.  Different molecular 
weight grades of polyethylene glycol (PEG) excipients were evaluated and PEG 1000 was 
5 
 
further incorporated into a formulation.  The formulation was tracked on stability to show the 
benefits of the modified ASTM E 299-08 method in a real-life scenario.  The ability for the 
modified ASTM E 299-08 method to detect total peroxide levels, in terms of active oxygen, and 
the ability to calculate the specific peroxide levels enables quick screening by one sole method.   
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CHAPTER 2.  Modifications to the ASTM E 299-08 Method 
 
Purpose of the Research Performed 
The purpose of the research described in this chapter was to make procedural 
improvements to the ASTM E 299-08 method and then evaluate the effectiveness of the changes 
by quantifying the active oxygen levels in solutions spiked with hydrogen peroxide. 
 
2.1.  Introduction 
 The ASTM E 299-08 method, titled Standard Test Method for Trace Amounts of 
Peroxides in Organic Solvents, was originally approved in 1966 with updated editions in 2002 
and 2008.  The intended significance for use of the method was defined as a procedure for 
determining the peroxide or active oxygen level in organic solvents.  The need for the general 
standard was justified by the explanation that dilute solutions of peroxides in organic solvents are 
used as catalysts and reaction initiators, and can be formed through autoxidation.  The formation 
of peroxides through autoxidation can lead to safety hazards; so quantification of the peroxide 
levels is important.
1
   
 The ASTM E 299-08 method claimed that the method can quantify active oxygen in the 
range from 5 to 80 µg/g (ppm) or higher and is specific to saturated and aromatic hydrocarbons, 
alcohols, ethers, ketones, esters, olefinic solvents, and some compounds that contain α, β, and 
conjugated unsaturation.
1
  The procedural components were modified in order to broaden the 
scope of the method for incorporation of excipients and to improve efficiency.  Dichloromethane 
replaced chloroform in the 2:1 acid solution mixture of acetic acid: chloroform used for diluting 
the samples.
1
   Dichloromethane has similar functionality to chloroform, but is less toxic and is 
more commonly used as a solvent. Another modification was the elimination of the special 
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absorption cell, adapted from ref 1. and represented in Figure 2.1, for measurement of low active 
oxygen levels.
1,2
  The cell is a custom piece of glassware that is not commercially available, 
which decreased the ease of access to the method.  To replace the cell, a 20 mL glass GC 
headspace vial with screw cap septum and a 5.75 inch glass pipette technique was used in order 
to protect the sample from air during the entire analysis.   
 
 
Figure 2.1: Special Custom Glass Absorption Cell for Low-Active Oxygen Levels Used in 
   ASTM E 299-08 Method
1 
 
Contrary to the ASTM E 299-08 method, which analyzed peroxides in organic solvents and 
unsaturates, the objective of this thesis is to measure active oxygen in pharmaceutical 
excipients.
2,3,4
  Pharmaceutical excipients have a wide range of physicochemical properties, 
which makes the use of a standardization blank important.
6
  Methanol was used as the blank 
solvent because it remains colorless during analysis and is inert in the reaction.
3,4
  To show the 
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accuracy of the modified ASTM E 299-08 method, varying levels of hydrogen peroxide (H2O2) 
spikes were evaluated.   
 
2.2.  Experimental 
An acid solution was prepared by combining 500 mL of glacial acetic acid, 350 mL of 
dichloromethane, and 30 mL of deionized water and mixing well.  A fresh aqueous potassium 
iodide solution (1 g/mL) was prepared immediately before sample preparation in order to 
minimize introduction of oxygen from the air.  The potassium iodide solution was prepared by 
accurately weighing and transferring 15 g of potassium iodide (1 g for each sample) to a 50 mL 
plastic centrifuge tube with printed graduations. The solid was dissolved and diluted to 15 mL (1 
mL for each sample) with deionized water, mixed well, and covered with aluminum foil.  A gas 
regulator with a pressure gauge attached to a nitrogen inlet and connected to a small diameter 
tubing was used to keep a consistent and precise flow of nitrogen through the samples during 
purging.  The potassium iodide solution was purged with nitrogen for about 20 minutes and then 
capped.  Blank sample solutions were prepared by accurately transferring 5 mL of methanol 
using glass pipettes to 15 mL plastic centrifuge tubes with printed graduations.  The methanol 
blank solutions were diluted to volume with the acid solution and directly transferred to glass 20 
mL gas chromatography (GC) headspace vials that had screw cap septa.   
A timer was set to 3 minutes and the nitrogen filled tubing was placed directly in to the 
glass GC headspace vials containing the methanol blank solutions in order to purge the sample.  
After 2 minutes of purging, 1 mL of aqueous potassium iodide solution was added via a positive 
displacement pipette and the solutions continued to be purged for an additional 1 minute.  After a 
total of 3 minutes of purging, the solutions were immediately capped as the tubing was removed, 
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covered with aluminum foil, and kept out of light for 1 hour.  It was critical to cap the GC 
headspace vials immediately to eliminate the possibility of air entering the vials and contributing 
to the active oxygen levels.  After 1 hour protected from light, the samples were removed.  Using 
5.75 inch glass pipettes, 1 mL aliquots were removed from the samples and transferred to a 1 cm 
quartz cuvette and analyzed at two different wavelengths.  A Beckman Coulter DU 800 
spectrophotometer was used to obtain absorbance values at 410 nm and 470 nm using the 
instrument method in Table 2.1. 
Table 2.1: Instrument Method for Beckman Coulter DU 800 Spectrophotometer 
Instrument Beckman Coulter DU 800 Spectrophotometer 
Detection Wavelength 410 nm and 470 nm 
Read Mode Absorbance 
Read Average Time 5 seconds 
 
The absorbance units for the methanol blank solutions were low in magnitude: ≤ 0.0500 AU at 
410 nm and ≤ 0.0100 AU at 470 nm.  The blank absorbance units were subtracted from the 
absorbance measurements of the samples to ensure that the calculated active oxygen levels were 
solely from the samples.   
In order to cover a wide range of 0-600 µg of active oxygen, two calibration curves were 
prepared.  The high range active oxygen curve was prepared to cover high magnitude levels from 
0 to 600 µg of active oxygen.  To produce the high range curve, iodine (0.064 g) was transferred 
into a 100 mL volumetric flask and diluted to volume with the acid solution to obtain a 0.64 mg 
iodine/mL stock solution.  The stock solution contained 0.64 mg iodine/mL, which was 
equivalent to 40.0 µg active oxygen/mL.
1
  The 40.0 µg active oxygen/mL stock solution was 
used to spike samples to produce a six point calibration curve.  Aliquots of 0, 1.5, 5, 8, 13, and 
15 mL of the stock solution were transferred to 15 mL centrifuge tubes and filled to volume with 
the acid solution.  The calibration standards were representative of 0.0, 60.2, 200.6, 321.0, 521.6, 
10 
 
and 601.9 µg of active oxygen. The active oxygen levels of the standards were measured by the 
modified ASTM E 299-08 method and the absorbance values of each standard were measured at 
410 nm and 470 nm.   
The low range active oxygen curve was prepared to cover low magnitude levels from 0 to 
40 µg of active oxygen, which is the region where the high range calibration curve lacked 
specificity.
1
  To produce the low range curve, iodine (0.064 g) was transferred into a 100 mL 
volumetric flask and diluted to volume with the acid solution to obtain a 0.64 mg iodine/mL 
stock solution.  The stock solution was further diluted by transferring 10 mL of the 0.64 mg 
iodine/mL solution into a 100 mL volumetric flask and diluting to volume with the acid solution.  
The new stock solution contained 0.064 mg iodine/mL, which was equivalent to 4.0 µg of active 
oxygen/mL.
1
  The 4.0 µg of active oxygen/mL stock solution was used to spike samples to 
produce a six point calibration curve.  Aliquots of 0, 1, 3, 5, 8, and 10 mL of the stock solution 
were transferred to 15 mL centrifuge tubes and filled to volume with the acid solution.  The 
calibration standards were representative of 0.0, 4.1, 12.2, 20.4, 32.6, and 40.7 µg of active 
oxygen. The active oxygen levels of the standards were measured by the modified ASTM E 299-
08 method and the absorbance values of each standard were measured at the 410 nm wavelength.   
To show the accuracy of the modified ASTM E 299-08 method, varying levels of 
hydrogen peroxide (H2O2) spikes were evaluated.  A 30% w/w hydrogen peroxide solution was 
obtained from EMD and diluted with water to obtain a 7.5% hydrogen peroxide solution.  Spiked 
volumes of 1 µL, 3 µL, 5 µL, 8 µL, and 10 µL of the H2O2 stock solution were added to 15 mL 
centrifuge tubes.  The H2O2 spikes were then diluted to volume with the acid solution to produce 
83.25 µg, 249.75 µg, 416.25 µg, 666.00 µg, and 832.50 µg H2O2 samples.  To convert µg of 
peroxide to µg of active oxygen, the following formula was used: 
11 
 
Peroxide X (µg) = active oxygen in sample (µg) x F 
where F is the conversion factor for peroxide X.
5
  Conversion factors for peroxides are calculated 
by dividing the molecular weight of the peroxide by the molecular weight of oxygen (16 g/mol).
5
 
H2O2 has a molecular weight of 34 g/mol and therefore a conversion factor, F, of 2.125.  The 
calculated theoretical amounts of active oxygen in the H2O2-spiked samples were 39.16 µg, 
117.53 µg, 195.88 µg, 313.41 µg, and 391.76 µg of active oxygen respectively.  A summary of 
the calculated theoretical amounts of H2O2 (µg) and corresponding active oxygen (µg) in the 
H2O2-spiked samples is presented in Table 2.2. The H2O2-spiked samples were transferred to 20 
mL GC headspace vials and the active oxygen levels were measured by the modified ASTM E 
299-08 method.   
Table 2.2: Calculated Theoretical Amount of Active Oxygen and Corresponding Amount of 




of Active Oxygen (µg) 
Theoretical Amount 
of H2O2 (µg) 
1 39.16 83.25 
3 117.53 249.75 
5 195.88 416.25 
8 313.41 666.00 
10 391.76 832.50 
 
 
2.3.  Results and Discussion 
The absorbance values, after methanol blank subtraction, for the high range iodine 
standards are presented in Table 2.3 and the calibration curves at the 410 nm and 470 nm 














Abs @ 410 nm 
(AU) 
Abs @ 470 nm 
(AU) 
1 0 0.0 0.0 0.0235 0.0017 
2 1.5 63.6 60.2 1.4407 0.2428 
3 5 212.0 200.6 2.8369 0.6726 
4 8 339.2 321.0 2.7678 1.0437 
5 13 551.2 521.6 2.7808 1.6912 
6 15 636.0 601.9 2.8079 1.9352 
 
Figure 2.2: High Range Active Oxygen Calibration Curve for Iodine Absorbance at the  



























Figure 2.3: High Range Active Oxygen Calibration Curve for Iodine Absorbance at the 
     470 nm Wavelength  
 
The calibration curve presented in Figure 2.2 showed that the absorbance readings at 410 
nm reached a maximum at 2.8 AU; hence that wavelength was not suitable for measurement of 
high active oxygen levels.  In contrast, the absorbance readings at 470 nm, presented in Figure 
2.3, produced a linear curve corresponding to the following equation: 
y = 0.0032x + 0.027 
where x is the amount of active oxygen and y is the absorbance measurement at 470 nm.  As a 
quick estimation technique to evaluate the active oxygen levels in the standards, the appearance 
of the samples after analysis can be utilized.  The colorimetric trend observed in the calibration 





y = 0.0032x + 0.027 
































Figure 2.4: Colorimetric Observation of the Iodine Calibration Standards (Following Active  
Oxygen Analysis) 
 
The absorbance values, after methanol blank subtraction, for the low range iodine 
standards are presented in Table 2.4 and the calibration curve at the 410 nm wavelength is 
presented in Figure 2.5.   
Table 2.4: Summary Table of Iodine Absorbance Results for the Low Range Active Oxygen 
Calibration Curve 
Std 





Abs @ 410 nm 
(AU) 
1 0 0.0 0.0 0.0308 
2 1 4.3 4.1 0.1344 
3 3 12.9 12.2 0.3104 
4 5 21.5 20.4 0.4928 
5 8 34.4 32.6 0.7985 








Figure 2.5: Low Range Active Oxygen Calibration Curve for Iodine Absorbance at the      
                              410 nm Wavelength 
 
 
The calibration curve presented in Figure 2.5 showed that the absorbance readings at 410 
nm produced a linear curve corresponding to the following equation: 
y = 0.0234x + 0.0299 
where x is the amount of active oxygen and y is the absorbance measurement at 410 nm.  The 
colorimetric trend observed in the calibration standards that represent the low magnitude active 








y = 0.0234x + 0.0299 




































Figure 2.6: Colorimetric Observation of the Iodine Calibration Standards (Following Active 
  Oxygen Analysis) 
 
The linear equations produced from the calibration curves can be used for quantitation of 
unknown levels of active oxygen in sample solutions.  Absorbance readings can be measured at 
both the 410 nm and 470 nm wavelengths and, depending on the magnitude of the absorbance, 
the appropriate calibration curve can be used. 
The absorbance results for the H2O2-spiked samples at 470 nm were within the limits of 
the high range calibration curve.  The absorbance results at 470 nm, with the methanol blank 
subtracted, are presented in Table 2.5 along with the measured amount of active oxygen (µg) 








0.0 4.1 12.2 20.4 32.6 40.7 
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Table 2.5: Absorbance Measurements, Amount of Active Oxygen and Corresponding 
Amount of H2O2 in the H2O2-Spiked Samples 
Spiked H2O2 
Vol. (µL) 






1 0.1304 32.30 68.64 
3 0.4148 121.17 257.49 
5 0.7001 210.33 446.95 
8 1.0759 327.22 695.34 
10 1.4015 429.52 912.73 
 
The appearance for the H2O2-spiked samples following active oxygen analysis is presented in 
Figure 2.7, along with the corresponding measured active oxygen levels (µg).   In Figure 2.8, 
the measured active oxygen results are plotted against the calculated theoretical active oxygen 









Figure 2.7: Appearance of the H2O2-Spiked Samples (Following Active Oxygen Analysis) 
 
 
Sample 1 µL Spike 3 µL Spike 5 µL Spike 8 µL Spike  10 µL Spike 




Figure 2.8: Measured Active Oxygen Results and Theoretical Active Oxygen Levels for the  
  H2O2-Spiked Samples 
 
The measured and theoretical levels of active oxygen in the H2O2-spiked samples were 
within 5% error, except for the 10 µL spiked sample.  The measured active oxygen levels began 
to trend higher than the theoretical levels because the method was measuring the total active 
oxygen produced from H2O2 and all other possible sources.  The more concentrated H2O2 sample 
could have had more heat develop from decomposition, which then raised the temperature of the 
solution and increased the production of total active oxygen.
7 
 
2.4.  Conclusions 
 The modifications made to the ASTM E 299-08 method added no limitations to the 
ability to detect active oxygen and varying spiked levels of H2O2 were successfully quantified.  
The modifications to the ASTM E 299-08 method were improvements that made the method 
more robust.  The glassware and solvents used in the modified method are routinely used in 






























methanol as the blank will be of importance for dilution purposes when both solid and liquid 
excipients are evaluated.  The iodine calibration curves were also prepared to measure very low 
levels of active oxygen in samples, which supports the future claim that the modified method can 
detect trace levels of active oxygen. 
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CHAPTER 3.  Evaluation of Known Organic Peroxides 
 
Purpose of the Research Performed 
The purpose of the research described in this chapter was to evaluate the active oxygen 
levels in spiked samples of hydroperoxide (ROOH) and peroxide (ROOR) compounds, to 
highlight the versatility of the modified ASTM E 299-08 method for active oxygen analysis of 
different types of peroxy compounds. 
 
3.1.  Introduction 
 Previous methods and techniques in the literature are limited in the range of peroxy 
compounds they can measure –  e.g., H2O2, hydroperoxides, or a specific known peroxide.
1,2,3
  
The modified ASTM E 299-08 method is capable of measuring all three types of peroxides at 
once and is not specific to one over the others.  The method’s wide scope of peroxy detection is 
important because excipients can contain multiple impurities, generally unidentified, that 
together represent the total active oxygen in the excipient.
4
  Representative organic peroxide 
compounds of different structural types were therefore selected for evaluation using the modified 
ASTM E 299-08 method.   
An organic hydroperoxide, tert-butyl hydroperoxide (TBHP), presented in Figure 3.1, 




Formula Weight : 90.12
Formula : C4H10O2  
Figure 3.1: Structure of tert-Butyl Hydroperoxide 
Organic hydroperoxides serve as autocatalytic intermediates in oxidation reactions of organic 
molecules by molecular oxygen.
5
  It is important when evaluating excipient stability that the 
modified active oxygen method can detect organic hydroperoxides if the excipients begin to 
degrade by oxidation.  In addition to being an autocatalytic intermediate, TBHP serves as an 
initiator along with cumene hydroperoxide, acetyl peroxide, benzoyl peroxide, and methyl amyl 
ketone peroxide.
6
   
A peroxide compound, dibenzoyl peroxide (DBPO), shown in Figure 3.2, was evaluated 
to highlight the claim that the modified method can detect active oxygen levels of the ROOR 
type compounds when there is no steric hindrance or thermal restrictions.  DBPO is 
representative of the ROOR functionality compounds, with R being a benzoyl group. 
Formula Weight : 242.2
Formula : C14H10O4  
Figure 3.2: Structure of Dibenzoyl Peroxide 
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DBPO is a reactive peroxide with a pi-bond system and aromatic rings.  The carbon structure is 
important when considering the reactivity of peroxides, specifically the ease of homolytic 
thermal dissociation of the peroxides.
5 
Stable di-tert-butyl alkyl peroxides are claimed not to react under the analysis conditions 
of the ASTM E 299-08 method.
6
  To verify this claim, di-tert-butyl peroxide (DTBP), shown in 
Figure 3.3, was evaluated.   DTBP is representative of the ROOR functionality compounds, with 
R being a tert-butyl group. 
Formula Weight : 146.23
Formula : C8H18O2  
Figure 3.3: Structure of di-tert-Butyl Peroxide 
DTBP contains two tert-butyl groups on either side of oxygen-oxygen bond, which can create 
steric hindrance making the compound not reactive to potassium iodide under the conditions of 
the modified ASTM E 299-08 method.  A temperature range from 90-130 °C is needed for 
DTBP to thermally decompose and be reactive.
7
  The temperature condition of the modified 
ASTM E 299-08 method was room temperature, around 25 °C, so it was hypothesized that the 
spikes of DTBP would not be detected. 
 
3.2.  Experimental 
Solutions with varying levels of TBHP spikes were prepared.  An 80% w/w TBHP 
solution in di-tert-butyl peroxide/water (3:2) was obtained from Sigma-Aldrich and diluted with 
the acid solution to obtain a 180.0 µg TBHP/µL stock solution.  Spiked volumes of 1 µL, 3 µL, 5 
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µL, and 10 µL of the TBHP stock solution were added to 15 mL centrifuge tubes.  The TBHP 
spikes were then diluted to volume with the acid solution to produce 180.0 µg, 540.0 µg, 900.0 
µg, and 1800.0 µg TBHP samples. TBHP has a molecular weight of 90.12 g/mol with a 
conversion factor, F, of 5.6325.  The calculated theoretical amounts of active oxygen in the 
TBHP-spiked samples were 31.96 µg, 95.87 µg, 159.78 µg, and 319.56 µg of active oxygen 
respectively.  A summary of the calculated theoretical amounts of TBHP (µg) and corresponding 
active oxygen (µg) in the TBHP-spiked samples is presented in Table 3.1. The TBHP-spiked 
samples were transferred to 20 mL GC headspace vials and the active oxygen levels were 
measured by the modified ASTM E 299-08 method.  Appearance was documented after active 
oxygen analysis was completed. 
Table 3.1: Calculated Theoretical Amount of Active Oxygen and Corresponding Amount of 




of Active Oxygen (µg) 
Theoretical Amount 
of TBHP (µg) 
1 31.96 180.0 
3 95.87 540.0 
5 159.78 900.0 
10 319.56 1800.0 
  
Solutions with varying levels of DBPO spikes were prepared.  A 1% w/w DBPO solution 
was prepared, by weighing 1 g of DBPO from ACROS Organics into 99 g (126 mL) of 
acetonitrile.  The density of the 1% w/w DBPO solution was measured to be 0.778 g/mL.  Spiked 
volumes of 61.9 µL, 185.8 µL, 309.6 µL, and 619.2 µL of the 7.8 µg DBPO/µL stock solution 
were added to 15 mL centrifuge tubes.  The spikes were then diluted to volume with the acid 
solution to produce 483.8 µg, 1451.5 µg, 2419.2 µg, and 4838.4 µg DBPO samples.  DBPO has 
a molecular weight of 242.2 g/mol with a conversion factor, F, of 15.139375.  The calculated 
theoretical amounts of active oxygen in the DBPO-spiked samples were 31.96 µg, 95.88 µg, 
159.80 µg, and 319.59 µg of active oxygen respectively.  A summary of the calculated 
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theoretical amounts of DBPO (µg) and corresponding active oxygen (µg) in the DBPO-spiked 
samples is presented in Table 3.2. The DBPO-spiked samples were transferred to 20 mL GC 
headspace vials and the active oxygen levels were measured by the modified ASTM E 299-08 
method.  Appearance was documented after active oxygen analysis was completed. 
Table 3.2: Calculated Theoretical Amount of Active Oxygen and Corresponding Amount of 




of Active Oxygen (µg) 
Theoretical Amount 
of DBPO (µg) 
61.9 31.96 483.8 
185.8 95.88 1451.5 
309.6 159.80 2419.2 
619.2 319.59 4838.4 
 
Solutions with varying levels of DTBP spikes were prepared.  A 98% DTBP solution was 
obtained from Sigma-Aldrich and diluted with acid solution tenfold to obtain a 79.6 µg 
DTBP/µL stock solution.  Spiked volumes of 1 µL, 3 µL, 5 µL, and 10 µL of the DTBP stock 
solution were added to 15 mL centrifuge tubes.  The spikes were then diluted to volume with the 
acid solution to produce 79.6 µg, 238.8 µg, 398.0 µg, and 796.0 µg DTBP samples.  DTBP has a 
molecular weight of 146.23 g/mol with a conversion factor, F, of 9.139375.  The calculated 
theoretical amounts of active oxygen in the DTBP-spiked samples were 8.71 µg, 26.13 µg, 43.55 
µg, and 87.10 µg of active oxygen respectively.  A summary of the calculated theoretical 
amounts of DTBP (µg) and corresponding active oxygen (µg) in the DTBP-spiked samples is 
presented in Table 3.3. The DTBP-spiked samples were transferred to 20 mL GC headspace 






Table 3.3: Calculated Theoretical Amount of Active Oxygen and Corresponding Amount   




of Active Oxygen (µg) 
Theoretical Amount 
of DTBP (µg) 
1 8.71 79.6 
3 26.13 238.8 
5 43.55 398.0 
10 87.10 796.0 
 
To eliminate the possibility of underestimating the concentration during sample 
preparation four additional DTBP-spiked samples were prepared in higher concentrations than 
the prior four samples.  A 98% DTBP solution was obtained from Sigma-Aldrich and transferred 
directly to 15 mL centrifuge tubes in spiked volumes of 1 µL, 3 µL, 5 µL, and 10 µL.  The spikes 
were then diluted to volume with the acid solution to produce 796.0 µg, 2388.0 µg, 3980.0 µg, 
and 7960.0 µg DTBP samples. The calculated theoretical amounts of active oxygen in the 
DTBP-spiked samples were 87.10 µg, 261.29 µg, 435.48 µg, and 870.96 µg of active oxygen 
respectively.  A summary of the calculated theoretical amounts of DTBP (µg) and corresponding 
active oxygen (µg) in the DTBP-spiked samples is presented in Table 3.4. The DTBP-spiked 
samples were transferred to 20 mL GC headspace vials and the active oxygen levels were 
measured by the modified ASTM E 299-08 method.   
Table 3.4: Calculated Theoretical Amount of Active Oxygen and Corresponding Amount of 




of Active Oxygen (µg) 
Theoretical Amount 
of DTBP (µg) 
1 87.10 796.0 
3 261.29 2388.0 
5 435.48 3980.0 







3.3.  Results and Discussion 
The absorbance result at the 410 nm wavelength for the 1 µL spiked TBHP sample was 
within the limits of the low range calibration curve.  The absorbance results for the remaining 
spiked samples at the 470 nm wavelength were within the limits of the high range calibration 
curve.  The absorbance results at 410 nm and 470 nm, with the methanol blank subtracted, are 
presented in Table 3.5 along with the measured amount of active oxygen (µg) and corresponding 
measured amount of TBHP (µg) in the samples.  The appearance for the TBHP-spiked samples 
following active oxygen analysis is presented in Figure 3.4, along with the corresponding 
measured active oxygen levels (µg).   In Figure 3.5, the measured active oxygen results are 
plotted against the calculated theoretical active oxygen levels, from Table 3.1, for the TBHP-
spiked samples. 
Table 3.5: Absorbance Measurements, Amount of Active Oxygen, and Corresponding 




Absorbance @ 470 nm (AU) 





1 0.8058 33.16 186.78 
3 0.3281 94.09 529.99 
5 0.5405 160.47 903.90 

















Figure 3.4: Appearance of the TBHP-Spiked Samples (Following Active Oxygen Analysis) 
 
 
Figure 3.5: Measured Active Oxygen Results and Theoretical Active Oxygen Levels for the 
  TBHP-Spiked Samples 
 
The measured and theoretical levels of active oxygen for the TBHP-spiked samples were within 
5% error.  The measured values began to trend higher than the theoretical because the method is 
measuring total active oxygen in the sample and not just the active oxygen produced solely from 


























Sample 1 µL Spike 3 µL Spike 5 µL Spike 10 µL Spike 
Active Oxygen (g) 33.16 94.09 160.47 336.41 
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The absorbance results at the 470 nm wavelength for the DBPO-spiked samples were 
within the limits of the high range calibration curve.  The absorbance results at the 470 nm 
wavelength, after methanol blank subtraction, are presented in Table 3.6 along with the 
measured amount of active oxygen (µg) and corresponding measured amount of DBPO (µg) in 
the samples. The appearance for the DBPO-spiked samples are presented in Figure 3.6, along 
with the corresponding measured active oxygen levels (µg).  In Figure 3.7, the measured active 
oxygen results are plotted against the calculated theoretical active oxygen levels, from Table 3.2, 
for the DBPO-spiked samples. 
Table 3.6: Absorbance Measurements, Amount of Active Oxygen, and Corresponding  
Amount of DBPO in the DBPO-Spiked Samples 
 
Spiked DBPO Vol. 
(µL) 






61.9 0.1114 26.36 399.07 
185.8 0.3400 97.80 1480.63 
309.6 0.5646 167.98 2543.11 












Figure 3.6: Appearance of the DBPO-Spiked Samples (Following Active Oxygen Analysis) 
 
Sample Spike 61.9 µL  185.8 µL  309.6 µL  619.2 µL  




Figure 3.7: Measured Active Oxygen Results and Theoretical Active Oxygen Levels for the  
  DBPO-Spiked Samples 
 
The measured and theoretical levels of active oxygen in the DBPO-spiked samples were within 
5% error, except for the 619.2 µL spiked sample.  The measured active oxygen levels began to 
trend higher than the theoretical levels because the method was measuring the total active 
oxygen produced from DBPO and all other possible sources.  The increased amount of DBPO in 
the sample could have led to more radical-initiated side reactions that produced more total active 
oxygen.
8
   
The absorbance results at the 410 nm wavelength for the low and high concentration 
spiked DTBP samples were within the limits of the low range calibration curve.  The absorbance 
results at the 410 nm wavelength, after methanol blank subtraction, are presented in Table 3.7 
and Table 3.8 along with the measured amount of active oxygen (µg) and corresponding 
measured amount of DTBP (µg) in the samples. In Figure 3.8, the measured active oxygen 
results are plotted against the calculated theoretical active oxygen levels, from Table 3.3 and 




























Table 3.7: Absorbance Measurements, Amount of Active Oxygen and Corresponding 
Amount of DTBP in the Low Concentration DTBP-Spiked Samples 
Spiked DTBP 
Vol. (µL) 






1 0.0282 not detected 0.00 
3 0.0364 0.28 2.56 
5 0.0284 not detected 0.00 
10 0.0304 0.02 0.18 
 
Table 3.8: Absorbance Measurements, Amount of Active Oxygen, and Corresponding 
Amount of DTBP in the High Concentration DTBP-Spiked Samples 
Spiked DTBP 
Vol. (µL) 






1 0.0380 0.34 3.11 
3 0.0298 not detected 0.00 
5 0.0364 0.28 2.56 




Figure 3.8: Measured Active Oxygen Results and Theoretical Active Oxygen Levels for the 
  DTBP-Spiked Samples 
 
The measured active oxygen levels for the high and low concentration DTBP-spiked samples did 































3.4.  Conclusions 
Successful detection of active oxygen in the TBHP- and DBPO-spiked samples verified 
that the modified ASTM E 299-08 method can detect peroxides of the ROOH and ROOR type.  
The modified active oxygen method could not detect active oxygen in the DTBP-spiked samples.  
With successful detection of active oxygen in the DBPO- and not the DTBP-spiked samples, the 
previous hypothesis was confirmed that the bulky R groups in DTBP created steric hindrance 
and thermal stability and thus was not reactive to the conditions of the method.  However, the 
ability of the modified ASTM E 299-08 method to detect peroxides of different types, gave 
confidence that the method would be able to detect unknown, unique, and complex peroxides 
present in liquid and solid excipients. 
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CHAPTER 4.  Active Oxygen Detection in Liquid Excipients 
 
Purpose of the Research Performed 
The purpose of the research described in this chapter was to test the applicability of the 
modified ASTM E 299-08 method to liquid excipients and to assess active oxygen levels in a 
select set of liquid excipients. 
 
4.1.  Introduction 
One of the main challenges in pharmaceutical development is creating formulations for 
poorly water-soluble drugs that have slow, incomplete dissolution and low bioavailability.  With 
over 40% of the new drug candidates in the development pipeline having active pharmaceutical 
ingredients (API) with low aqueous solubility, the need for innovative formulations is critical.
1
  
Lipid-based drug delivery systems (LBDDS) are one of the innovative formulation techniques 
utilized to help improve API solubility.
2
  Common solubilizing excipients used in commercially 
available lipid-based formulations were reviewed and examples from the following three classes 
were selected for evaluation: water-insoluble, triglyceride, and surfactant.
2 
 The liquid excipients 
chosen were oleic acid and propylene glycol from the water-insoluble class, tall oil from the 
triglyceride class, and polysorbate 20, polyethylene glycol 400 (PEG 400), Kolliphor® EL, and 
polysorbate 80 from the surfactant class.  These liquid excipients are commonly used in 
formulations; so it is beneficial to pharmaceutical scientists to know the active oxygen levels in 
them. 
Liquid excipients with different functionalities were selected to perform a broad screen of 
the active oxygen levels.  The excipients chosen, their excipient functionality, density, and 




Table 4.1: Liquid Excipients Used in Screening of Active Oxygen Levels
 




Polyethylene Glycol 400 Coating Agent, lubricant
4,5 1.126 Sigma-Aldrich 






8 1.050 Sigma-Aldrich 
Polysorbate 20 
Solubilizing agent, nonionic 
surfactant
9,10 1.105 Alfa Aesar 






13 1.036 Spectrum 
Polysorbate 80 Nonionic surfactant
14,15
 1.064 Fluka 
 
The density values for each excipient were included in Table 4.1 because the density values will 
be used in the conversion of active oxygen from µg to ppm for each sample. 
 
4.2.  Experimental 
Sample solutions of the liquid excipients were prepared in order to analyze them by the 
modified ASTM E 299-08 method.  The samples were prepared in duplicate to measure the 
consistency of the modified active oxygen method within the same excipient.  A 5 mL volume of 
each liquid excipient was transferred to 15 mL centrifuge tubes and diluted to volume with the 
acid solution.  The liquid excipients were mixed with the acid solution, transferred to 20 mL GC 
headspace vials, and then the vials were kept capped pending analysis.  Before active oxygen 
analysis, any liquid excipients that were yellow in appearance also required a color blank to be 
prepared for that sample (2 mL of the excipient: 4 mL of the acid solution).  The color blanks 
were analyzed by the UV spectrophotometer as is and were not run under the conditions of the 
modified ASTM E 299-08 method.  Subtraction of the sample color blank eliminated any 
interference in the absorbance measurements due to intrinsic coloration of the liquid excipient 
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being tested.  The excipients that were yellow in appearance and required color blanks were oleic 
acid, Kolliphor® EL, polysorbate 20, tall oil, and polysorbate 80.   The active oxygen levels of 
the liquid excipients were measured by the modified ASTM E 299-08 method and the 
absorbance results at the 410 nm and 470 nm wavelengths were recorded.  Appearance was 
documented after active oxygen analysis was completed. 
 
4.3.  Results and Discussion 
The absorbance results for the liquid excipients at the 410 nm and 470 nm wavelengths, 
after subtraction of the methanol blank and sample color blank if applicable, are presented in 
Table 4.2. 




The magnitude of the absorbance values for the liquid excipients, shown in Table 4.2, indicated 
that the active oxygen levels (µg) for each liquid excipient were calculated via the high range 
calibration curve, except for propylene glycol where the active oxygen level was calculated via 
Liquid Excipient Sample # Absorbance at 410 nm 
(AU) 




1 4.2666 1.1682 
2 4.2666 1.1596 
Oleic Acid 
1 3.8924 0.6985 
2 3.3484 0.4793 
Kolliphor® EL 
1 3.6350 1.9177 
2 3.4132 1.8630 
Polysorbate 20 
1 1.3069 0.1514 
2 1.2273 0.1427 
Tall Oil 
1 1.6944 0.2313 
2 1.3073 0.3948 
Propylene Glycol 
1 0.0342 0.0209 
2 0.0358 0.0284 
Polysorbate 80 
1 3.0885 2.0867 
2 3.0885 2.1231 
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the low range calibration curve.  The active oxygen results (µg) were calculated from the 
averaged (n=2) absorbance values.  To convert the active oxygen levels from µg to ppm for each 
excipient, the density of each excipient and the sample volume (5 mL) was used in the following 
calculation: 
          active oxygen (ppm) of excipient  =                     active oxygen (µg) of excipient1 
           excipient volume (mL) * density of excipient (g/mL) 
 
The calculated active oxygen levels in µg and ppm for each liquid excipient evaluated are 
presented in Table 4.3 in rank order from lowest active oxygen level to highest.    The 
corresponding appearance results for the liquid excipient samples are presented in Figure 4.1. 













Figure 4.1: Appearance of the Liquid Excipient Samples (Following Active Oxygen 
        Analysis) 
Liquid Excipient Active Oxygen Level (µg) Active Oxygen Level (ppm) 
Propylene Glycol 0.22 0.04 
Polysorbate 20 52.87 9.61 
Tall Oil 62.86 14.00 
Oleic Acid 175.59 39.46 
Polyethylene Glycol 400 355.28 63.11 
Kolliphor® EL 582.30 110.91 


















0.04 9.61 14.00 39.46 63.11 110.91 122.06 
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The oleic acid and tall oil samples were not miscible with the 1 mL addition of the 
aqueous KI solution spike and formed non-homogeneous mixtures that had high background 
absorbance.  The duplicates of the fatty acid samples had differences in absorbance units of 0.22 
AU (oleic acid) and 0.16 AU (tall oil), while the other liquid excipients only had a difference in 
absorbance units of 0.002-0.05 AU.  The non-homogeneous appearance of those two fatty acid 
samples could have led to different absorbance readings depending on the layer of the aliquot 
that was measured by the spectrophotometer.  A comparison plot of the active oxygen levels for 
each liquid excipient, displayed in Figure 4.2, demonstrated the broad range that the modified 
ASTM E 299-08 method covered. 
 
Figure 4.2: Active Oxygen Levels Measured for Each Liquid Excipient 
 
 
4.4.  Conclusions 
The modified ASTM E 299-08 method successfully measured the active oxygen levels in 





























Excipient Rank Order  
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possessed widely varying physical characteristics, but the modified method was non-
discriminatory and levels in the range of 0.22 µg – 649.34 µg (0.04 ppm – 122.06 ppm) of active 
oxygen were quantified.  The fatty acid excipients showed some limitations for quantification 
within the duplicate samples because of the incompatibility of the excipient with the aqueous KI 
solution.  A possible solution for this inconsistency would be to dilute the initial liquid excipient 
sample with methanol to expose less of the excipient to the aqueous KI solution.  The dilution 
would be accounted for in the final calculation and the duplicate results may then have better 
agreement. 
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CHAPTER 5.  Active Oxygen Detection in Solid Excipients 
 
Purpose of the Research Performed 
The purpose of the research described in this chapter was to test the applicability of the 
modified ASTM E 299-08 method to solid excipients and to assess active oxygen levels in a 
select set of solid excipients. 
 
5.1.  Introduction 
With the increased presence of API that have poor aqueous solubility, an emerging 
formulation development technique used to combat this issue in addition to LBDDS, is solid 
dispersion.  Solid dispersion is when one or more API is dispersed in an inert carrier or matrix in 
the solid-state phase and prepared by solvent, melting, or a combination of the two.
1
  Solid 
dispersions help formulate API compounds that belong to Class II in the Biopharmaceutics 
Classification System (BCS), which are described as poorly soluble and highly permeable.
1
  
Excipients used in commercially available solid dispersions were reviewed, and the solid 
excipients evaluated were from the following carrier types: povidone (PVP), polyethylene glycol 
(PEG), and poloxamer.
1 
 The specific solid excipients chosen were polyethylene glycol 1000 
(PEG 1000) from the PEG carrier type, polyvinylpyrrolidone 58 (K29-32) from the PVP carrier 
type, and poloxamer 188 from the poloxamer carrier type.  Myrj 52™ was also evaluated 
because it shares similar characteristics to poloxamer as an emulsifying agent and was also used 
in solid dispersion formulations.
2,3
  These solid excipients are commonly used in formulations; 
so it is beneficial to pharmaceutical scientists to know the active oxygen levels in them.  The 
solid excipients with different functionalities that were selected are listed in Table 5.1, along 





Table 5.1: Solid Excipients Used in Screening of Active Oxygen Levels 
Solid Excipient Excipient Classification Density (g/mL) Manufacturer 





Tablet and capsule binder, 
solubilizing agent
6,7 1.18 ACROS 
Myrj 52™ Emulsifying agent
2 
N/A S Pharma 
Poloxamer 188 
Emulsifying agent, nonionic 
surfactant
8,9 1.06 Spectrum 
 
The density values for each excipient are included in Table 5.1, but during the sample 
preparation the densities of the final excipient solutions were 1 g/mL.  The density values of the 
excipient solution will be used in the conversion of active oxygen from µg to ppm for each 
sample. 
 
5.2.  Experimental 
Sample solutions of the solid excipients were prepared in duplicate to measure the 
consistency of the modified ASTM E 299-08 method within the same excipient.  Ten grams of 
each solid excipient was transferred into 20 mL scintillation vials and methanol (10 mL) was 
added to the vials.  The sample was mixed until the solid excipient was dissolved and the 
solution was homogeneous with a density of 1 g/mL. The 1 g/mL methanolic solutions enabled 
the solid excipients to be evaluated in the same manner as the liquid excipients. The 1 g/mL 
density is equivalent to the averaged density (1.024 g/mL) for the previous liquid excipients 
evaluated in Chapter 4.  Five milliliters of the samples were transferred to 15 mL centrifuge 
tubes, diluted to volume with the acid solution, and mixed thoroughly.  The samples were 
transferred to 20 mL GC headspace vials and the vials were kept capped pending analysis.  
Before active oxygen analysis, any excipient solution that was yellow in appearance also 
required a color blank to be prepared (2 mL of the methanolic solution: 4 mL of the acid 
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solution). The color blanks were analyzed by the UV spectrophotometer as is and were not run 
under the conditions of the modified active oxygen method.  Subtraction of the sample color 
blank would eliminate any interference in the absorbance measurements from the intrinsic 
coloration of the excipient methanolic solution.  The solid excipient solution that was yellow in 
appearance before analysis and required a color blank was the K29-32 methanolic solution.   The 
samples were analyzed using the modified ASTM E 299-08 active oxygen method and the 
absorbance results were recorded at both the 410 nm and 470 nm wavelengths.   Appearance was 
documented after active oxygen analysis. 
 
5.3.  Results and Discussion 
The absorbance results at the 410 nm and 470 nm wavelengths for the solid excipients, 
after subtraction of the methanol blank and the sample color blank if applicable, are presented in 
Table 5.2. 
Table 5.2: Absorbance Measurements (n=2) for the Solid Excipients (Following Active 
Oxygen Analysis) 
 
The higher magnitude absorbance values of PEG 1000 and K29-32, in Table 5.2, indicated that 
the active oxygen levels (µg) for these two samples were calculated via the high range 
calibration curve.  The remaining excipients Myrj 52™ and poloxamer 188, in Table 5.2, had 
Solid Excipient Sample # Absorbance at 410 nm 
(AU) 




1 1.4330 0.1860 
2 1.4742 0.1970 
Polyvinylpyrrolidone 58 
(K29-32) 
1 3.9171 2.6460 
2 3.9229 2.4504 
Myrj 52™ 
1 0.1401 0.0184 
2 0.1167 0.0143 
Poloxamer 188 
1 0.0770 0.0123 
2 0.0712 0.0293 
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lower magnitude absorbance values, for which the low range calibration curve would be used.  
The active oxygen results (µg) are calculated from the averaged absorbance values (n=2).  To 
convert the active oxygen levels for each excipient from µg to ppm, the density of each sample 
solution (1 g/mL) and the sample volume transferred was used according to the following 
calculation: 
            active oxygen (ppm) of excipient =                     active oxygen (µg) of excipient1 
           excipient volume (mL) * density of excipient (g/mL) 
 
The calculated active oxygen levels in µg and ppm for the solid excipients are presented in 
Table 5.3 in rank order from lowest active oxygen level to highest.  The corresponding 
appearance of the solid excipient samples, after active oxygen analysis, is presented in Figure 
5.1. 









Figure 5.1: Appearance of the Solid Excipient Samples (Following Active Oxygen Analysis) 
Solid Excipient Active Oxygen Level (µg) Active Oxygen Level (ppm) 
Poloxamer 188 1.89 0.38 
Myrj 52™ 4.21 1.00 
Polyethylene Glycol 1000 51.39 10.26 
Polyvinylpyrrolidone 58 (K29-32) 787.88 156.85 
Sample Poloxamer 188 Myrj 52™ PEG 1000 K29-32 
Active Oxygen (ppm) 0.38 1.00 10.26 156.85 
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The duplicates prepared for the solid excipients poloxamer 188, Myrj 52™, and PEG 1000 had 
differences in absorbance units of 0.006-0.02 AU.  The duplicates prepared for K29-32 had a 
difference in absorbance units of 0.20 AU.  The higher difference in the K29-32 duplicates could 
be attributed to the fact that two separate samples of K29-32 were prepared on different days 
because on the first day of analysis there was not enough sample to have a duplicate analysis.   It 
was also observed that the physical characteristic of each solid excipient determined the length of 
time it took the methanolic solution to be homogeneous.  For example, PEG 1000 was a waxy 
solid and took longer to dissolve in methanol than poloxamer 188, which was a flake and had 
increased surface area for interaction with methanol.  A comparison of the active oxygen levels 
for these solid excipients, displayed in Figure 5.2, demonstrated the broad range that the 
modified ASTM E 299-08 method covered. 
 
 






























Excipient Rank Order  
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5.4.  Conclusions 
The modified ASTM E 299-08 method successfully measured the active oxygen levels in 
several solid excipients, without knowledge of the contributing peroxide.  The preparation of 
methanolic solutions for active oxygen analysis of solid excipients provided a comparable 
procedural method to the one used for liquid excipients.  The solid excipients possessed different 
physical characteristics, but the modified ASTM E 299-08 method was non-discriminatory and 
levels in the range of 1.89 µg – 787.88 µg (0.38 ppm – 156.85 ppm) of active oxygen were 
quantified.  Successful quantification of the active oxygen levels in solid excipients verified that 
the modified ASTM E 299-08 method is applicable for analysis of drug products that are solid 
dosage forms, such as powders or hot melts. 
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CHAPTER 6.  Active Oxygen Formation in PEG Excipients 
 
Purpose of the Research Performed 
The purpose of the research described in this chapter was to evaluate active oxygen 
formation in different molecular weight grade polyethylene glycol (PEG) excipients to determine 
if there were differentiating trends. 
 
6.1.  Introduction 
Polyethylene glycol (PEG) excipients were chosen for evaluation because they are known 
to have trace levels of oxidation products, e.g., peroxides, aldehydes, and organic acids.  The 
impurities in the PEG excipients have been linked to drug-excipient interactions that have led to 
instability of the drug product formulations due to degradation of the drug.
1
  The PEG 
compounds have been used as lubricants, plasticizers, solvents, softening agents, antiblooming 
agents, emulsifying agents, and cosmetic bases, but are known to be susceptible to autoxidative 
degradation when exposed to elevated temperatures in the presence of oxygen and water.
2,3
  The 
main site for oxidation of the PEG compounds
 
is expected to occur at the repeating ether bonds 
in the chain structures by a peroxidation reaction.
3
  The modified ASTM E 299-08 method was 
suitable to detect the complex peroxides resulting from the PEG compounds because it is non-
specific to the peroxides from which the active oxygen is derived. 
Two molecular weight grades (PEG 400 and PEG 4000) of PEG were evaluated for 
active oxygen formation.  The PEG excipients contained different physical characteristics – PEG 
400 was a liquid and PEG 4000 was a granular solid flake.  The average repeating oxyethylene 
units varied between the PEG grades: 8.7 repeating units for PEG 400 and 90.5 repeating units 
for PEG 4000.
4,5,6
  Lower molecular weight grade PEG compounds are more susceptible to 
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oxidation at low temperatures than higher molecular weight grade PEG compounds.
10
  The solid 
physical nature of the higher molecular weight compounds allow minimal internal surface area 
available for oxygen interaction and a higher resistance to oxidation.  The molecules in the lower 
molecular weight liquid PEG compounds have exposure to both external surface and internally 
dissolved oxygen.
9
  It has been reported in the literature that at higher temperatures the peroxides 
in the PEG compounds reach a steady-state concentration before a decrease in concentration.
2
  
The first-order rate constants for the degradation via autoxidation of the model glycol compound, 













 at 26 °C.
7
   
The peroxides in PEG compounds from radical-initiated or autoxidation reactions can 
lead to formation of other impurities such as aldehydes and organic acids.  The formation of 
formaldehyde, acetaldehyde, and formic acid in PEG 400 has previously been published and the 
14-day data set adapted from ref 1. is replotted in Figure 6.1 for ease of illustration.
1
  Formic 
acid was also included as a PEG impurity because formaldehyde can be converted to formic acid 
on contact with air.
8
  The calculated rate of formation of acetaldehyde, formaldehyde, and formic 
acid in PEG 400 from the initial level was 1.55 ppm/day for acetaldehyde, 2.82 ppm/day for 




Figure 6.1: Reactive Impurity Levels in Neat PEG 400 Samples Stored at 50 °C in Glass  
    Vials with Aluminum Crimped Rubber Septum
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The effect of additive peroxide, such as H2O2, on the growth of impurity formation in PEG 400 
has been previously published and the data adapted from ref 1. is replotted in Figure 6.2 for ease 
of illustration.
1  
The samples containing H202 versus the control samples were reported to have 
increased formic acid rates and an initial greater increase in formaldehyde.
1
 
y = 2.82x + 39.62 
y = 1.55x + 7.27 






























Figure 6.2: Reactive Impurity Levels in 1:1 PEG 400: H2O Samples With (dashed line) and 
  Without (solid line) Oxidation Inducers Stored at 40 °C in Glass Vials with  
  Aluminum Crimped Rubber Septum
1 
 
The proposed mechanisms for the oxidative formation of aldehyde, formaldehyde, and formic 
acid from PEG compounds are adapted and redrawn from ref. 1 and presented in Figure 6.3 and 

































Acetaldehyde Formaldehyde Formic Acid
Acetaldehyde (w/peroxide) Formaldehyde (w/peroxide) Formic Acid (w/peroxide)








































Figure 6.4: Mechanism for the Oxidative Formation of Formaldehyde and Formic 




The evaluation of the molecular weight grade PEG compounds, PEG 400 and PEG 4000, 
explored whether or not the active oxygen levels coincided with the impurity trends previously 
published for PEG 400.  The active oxygen evaluation also showed the similarities and 
differences between the different molecular weight grade PEG compounds. 
 
6.2.  Experimental 
The effect of a nitrogen overlay on active oxygen formation in PEG 400 at room 
temperature (25 °C) was evaluated.  Super Refined PEG 400 from CRODA was chosen because 
super refined lots historically have the highest purity and should have the lowest initial levels of 
active oxygen. Two bottles from the same lot were obtained.  One bottle was blanketed with 
nitrogen for 3 minutes after each sample pull and then capped.  The second bottle acted as a 
control and was not blanketed with nitrogen after each sample pull.  Sample pulls were taken at 
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levels were measured by the modified ASTM E 299-08 method.  Appearance of the samples was 
documented at each time point. 
Two molecular weight grades of PEG (PEG 400 and PEG 4000) were prepared for active 
oxygen analysis.  PEG 400, from ACROS Organics, was transferred in 15 mL aliquots to 20 mL 
scintillation vials.  PEG 4000, from ACROS Organics, was transferred and weighed (7 g) into 20 
mL scintillation vials.  The vials were capped and placed in stability chambers at 25 °C/60% RH 
and 40 °C/75% RH to be pulled and evaluated for active oxygen formation at initial, 2 days, 7 
days, and 14 days.  During each sample pull, methanol (7 mL) was added to the warmed (60 °C) 
solid PEG 4000 sample solutions, to form 1 g/mL methanolic solutions, and the liquid PEG 400 
samples were analyzed as is.  The active oxygen levels in the PEG stability samples were 
measured by the modified ASTM E 299-08 method.  Appearance of the PEG stability samples 
was documented after active oxygen analysis was completed. 
 
6.3.  Results and Discussion 
The averaged active oxygen results for the super refined PEG 400 lot with and without a 
nitrogen overlay are presented in Table 6.1.  A plot of the active oxygen levels over time for the 
PEG 400 lot, with and without a nitrogen overlay, is displayed in Figure 6.5.  Appearance of the 








Table 6.1: Averaged (n=2) Active Oxygen Results (ppm) for Super Refined PEG 400 With 
and Without Nitrogen Overlays 
Sample  Initial 1 week 2 week 4 week 8 week 
Bottle without N2 Overlay 0.36 2.97 4.90 10.58 16.57 










y = 2.04x + 0.96 
































Figure 6.6: Appearance of the Super Refined PEG 400 Samples With and Without a Nitrogen 
Overlay (Following Active Oxygen Analysis)  
 
 
Super refined PEG 400 showed a drastic jump in active oxygen levels when a nitrogen 
overlay was absent between sample pulls.  The rate of the active oxygen increase in the sample 
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was 2.04 ppm/week.  When the same lot was exposed to a nitrogen overlay between sample pulls 
the rate of active oxygen formation was decreased to 0.38 ppm/week.  
The active oxygen results for PEG 400 and PEG 4000 on stability are presented below in 
Table 6.2.  The corresponding plotted data and appearance are shown in Figure 6.7 and Figure 
6.8.   
Table 6.2: Active Oxygen Levels in PEG Compounds 
 
Active Oxygen Levels (ppm) 
PEG Sample PEG 400 PEG 4000 
Temperature 
25 °C 40 °C 25 °C 40 °C 
Time (day) 
0 57.20 57.20 nd nd 
2 57.56 56.15 nd nd 
7 63.53 34.22 nd nd 
14 63.38 9.70 nd nd 
Key nd – not detected 
 
 






























Figure 6.8: Appearance of PEG Compounds (Following Active Oxygen Analysis) 
 
The PEG 400 stability results, in Figure 6.7, showed a stable active oxygen level at       
25 °C/60% RH over 14 days and a steady state at 40 °C/75% RH between 0-2 days before a 




 at 40 
°C/75% RH after 14 days.  PEG 4000 had no detectable active oxygen levels at 25 °C/60% RH 
and 40 °C/75%RH.  The decay rate at 40 °C/75% RH for PEG 400 was three times greater than 
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The decrease in active oxygen for PEG 400 at 40 °C/75%RH was 3.57 ppm/day which was 
similar to the formation rate of formic acid (3.94 ppm/day) published in the literature.
1
  The 
similarity of the rates between the decrease of active oxygen and the formation of formic acid 
supported the hypothesis that peroxides initiate the formation of formic acid in PEG 400.  The 
result demonstrated that when peroxides are present in PEG 400, formic acid will increase to a 
greater extent than when peroxides are absent. 
 
6.4.  Conclusions 
The analysis of PEG 400 with and without a nitrogen overlay demonstrated that nitrogen 
incorporated into the storage of excipients can help reduce the rate of oxidative degradation 
reactions.  The PEG 400 sample without a nitrogen overlay had a 5.4 times faster formation rate 
of active oxygen compared to the sample that had a nitrogen overlay.  PEG 400 had a higher 
magnitude active oxygen decay rate than diethylene glycol, which confirmed that the repeating 
oxyethylene units in PEG 400 led to higher susceptibility to autoxidation.  PEG 400 was more 
susceptible to autoxidation than PEG 4000 because it was a liquid and a lower molecular weight.  
A liquid composition has more contact with internal and external oxygen than solids, which have 
contact with oxygen predominantly on the external surface.
9
  The susceptibility to oxidation for a 
compound also decreases with increase in molecular weight.
10 
  The modified ASTM E 299-08 
method successfully demonstrated the ability to account for peroxides that led to the decay rate 
of PEG purity and showed the differences in active oxygen levels between the dissimilar 
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CHAPTER 7.  Evaluation of CEP-701 Drug Product Stability by the Modified ASTM         
 E 299-08 Method 
 
Purpose of the Research Performed 
The purpose of the research described in this chapter was to evaluate the active oxygen 
formation in a model drug product whose formulation contained lestaurtinib (CEP-701), PEG 
1000, Myrj 52™, and water.  The goal was to quantify the active oxygen contribution from PEG 
1000, which led to the degradation of lestaurtinib (CEP-701). 
 
7.1.  Introduction 
A model drug product formulation was prepared containing the drug substance 
lestaurtinib, which is also known as CEP-701.  CEP-701 was developed by Cephalon (Frazer, 
PA, USA) and was incorporated in a formulation that contained PEG 1000 as one of the 
excipients.  CEP-701 is a fms-like tyrosine kinase 3 (FLT3) inhibitor studied for targeted therapy 
in the treatment of acute myelogenous leukemia (AML), where FLT3 mutations are present.
1
  
Fms is a proto-oncogene that is similar to the receptor for a macrophage colony-stimulating 
factor.
1
   Around 30% of AML patients have FLT3 mutations and the five-year survival rate for 
AML is about 26%.
5
  The chemical structure and some properties of CEP-701 are presented in 
Table 7.1.
1













Drug Name lestaurtinib , CEP-701 
Phase Phase III 
Indications acute myelogenous leukemia (AML) 
Pharmacology description fms-like tyrosine kinase 3 inhibitor 





The CEP-701 structure contains sites susceptible to oxidative degradation and 
hydroperoxide formation by peroxides and impurities found in PEG 1000.  The reaction scheme 
for oxidative degradation of CEP-701 is presented in Figure 7.1. The related impurities to PEG 
1000, specifically formic acid and its esters, can react with the nitrogen or oxygen of the amide 
functional group in CEP-701.
2
  The CEP-701 impurities related to formaldehyde and 
acetaldehyde addition to the 2-pyrrolidone ring are displayed in Figure 7.2.  The structures for 
compounds 7 – 9, have historically been isolated and characterized by Cephalon via nuclear 
magnetic resonance (NMR) spectroscopy and mass spectrometry. 
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Formula Weight : 439.5
Exact Mass : 439.153206
Formula : C26H21N3O4
Formula Weight : 471.5
Exact Mass : 471.143035
Formula : C26H21N3O6
Formula Weight : 455.5
Exact Mass : 455.148121
Formula : C26H21N3O5
Formula Weight : 453.4
Exact Mass : 453.132471
Formula : C26H19N3O5
CEP-701 (1) peroxy 2 (S) or peroxy 3 (R) 
hydroxy 4 (R) or hydroxy 5 (S)6
 
 








Formula Weight : 469.5
Exact Mass : 469.163771
Formula : C27H23N3O5
7
Formula Weight : 483.5




Formula Weight : 469.5




Figure 7.2: Structures of CEP-701 Impurity Compounds from Formaldehyde (7, 9) and  
                             Acetaldehyde (8) Addition 
 
The model formulation contained CEP-701, PEG 1000, polyoxyl (40) stearate (Myrj 
52™), and water. At each time point the stability samples were evaluated for active oxygen 
levels, assay, purity, and appearance. A side-by-side evaluation with both the modified ASTM E 
299-08 method and the HPLC assay method was intended to quantitatively show active oxygen 
formation as well as the formation of CEP-701 degradative impurities.  In addition to the drug 
product, a placebo and individual PEG 1000 and Myrj 52™ samples were evaluated on stability 
for active oxygen levels and appearance.  Analysis of the placebo and the excipients explored 
whether the active oxygen levels could be accounted for as being derived from PEG 1000 alone 
or if the combination of excipients led to the active oxygen level of the drug product. 
The CEP-701 drug product stability samples were evaluated under three different vial 
conditions: capped, capped with nitrogen overlay, and uncapped.  The observation was 
previously reported in Chapter 6 that nitrogen reduces the rate of active oxygen formation in 
PEG excipients.  The capped with nitrogen overlay vial condition for the drug product should 
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exhibit the same behavior and reduce the rate of active oxygen formation in the samples.  
Capped versus uncapped vials were evaluated to see if the amount of oxygen available in the 
sample impacted the rate of active oxygen formation in the drug product.  The capped storage 
condition was oxygen-limiting, while the uncapped storage condition had no limits on oxygen 
exposure.  The excipient and placebo samples were only evaluated under the capped vial 
condition because it was representative of commercial drug product storage. 
The CEP-701 drug product stability samples were evaluated under four different 
temperature conditions: 5 °C, 25 °C/60% RH, 30 °C/65% RH, and 40 °C/75% RH.  According to 
the FDA Guidance for Industry Q1A(R2), Stability Testing of New Drug Substances and 
Products, the recommended storage temperatures for a drug product are: long-term storage at    
25 °C/60% RH or 30 °C/65% RH, intermediate storage at 30 °C/65% RH, and accelerated 
storage at 40 °C/75% RH.
3
  The long-term storage is recommended for 12 months and the 
intermediate and accelerated storage is recommended for 6 months.  The recommendations for 
drug products intended for storage in a refrigerator are: long-term storage at 5 °C for 12 months 
and accelerated storage at 25 °C/60% RH for 6 months.
3
  The CEP-701 drug product stability 
samples were treated as samples that required long-term storage at both refrigerated (5 °C) and 
30 °C/65 % RH.  The corresponding accelerated conditions used were 25 °C/60% RH and        
40 °C/75% RH.  The melting point range of PEG 1000 was 37-40 °C, which indicated that 
storage at 40 °C/75% RH may have been too aggressive and melting of PEG 1000 could have 
manipulated the active oxygen levels.
4
  To be proactive in case the 40 °C/75% RH condition was 
too aggressive, the samples at 25 °C/60% RH were held for 12 months as a backup to the          
30 °C/65% RH long-term storage condition.  If the 25 °C/60% RH condition became the long-
term condition then the 30 °C/65% RH condition, would become the accelerated condition.  To 
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cover each temperature condition, the CEP-701 drug product was placed on stability following 
the stability study plan presented in Table 7.2.  
Table 7.2: Stability Study Plan for the CEP-701 Drug Product 
Condition Initial 1 Month 2 Month 3 Month 6 Month 9 Month 12 Month 
5 °C
 
X, Y, Z X, Y, Z X, Y, Z X, Y, Z X, Y, Z (X, Y, Z) X, Y, Z 
25 °C/60% RH X, Y, Z X, Y, Z X, Y, Z X, Y, Z X, Y, Z (X, Y, Z) (X, Y, Z) 
30 °C/65% RH X, Y, Z X, Y, Z X, Y, Z X, Y, Z X, Y, Z (X, Y, Z) X, Y, Z 
40 °C/75% RH X, Y, Z X, Y, Z X, Y, Z X, Y, Z (X, Y, Z) (X, Y, Z) (X, Y, Z) 
Key X - Capped, Y – Uncapped, Z – Capped w/N2 Overlay, ( ) – Optional Pull 
 
  The stability study plan for the drug product placebo and the individual excipients is 
presented in Table 7.3.  The placebo was evaluated at all four temperatures (5 °C, 25 °C/60% 
RH, 30 °C/65% RH, and 40 °C/75% RH) and the individual excipients were evaluated at  5 °C, 
30 °C/65% RH, and 40 °C/75% RH. 
Table 7.3: Stability Study Plan for the Drug Product Placebo and Excipients 
Condition Initial 1 Month 2 Month 3 Month 6 Month 9 Month 12 Month 
5 °C
 
P, E P, E P, E P, E P, E (P, E) (P, E) 
25 °C/60% RH P P P P P (P) (P) 
30 °C/65% RH P, E P, E P, E P, E P, E (P, E) (P, E) 
40 °C/75% RH P, E P, E P, E P, E (P, E) (P, E) (P, E) 
Key P - Placebo,  E – Excipients,  ( ) – Optional Pull 
 
 
7.2.  Experimental 
The model formulation contained CEP-701, PEG 1000, Myrj 52™, and water. Due to the 
susceptibility of CEP-701 drug substance to degradation by light, the formulation process was 
performed under yellow light.  Prior to formulation, the CEP-701 drug substance was sieved to 
achieve a 125 µm particle size for improved dissolution in order to minimize exposure to heat 
and light.  A 610 g batch of drug product was prepared at a 50 mg/g (55 mg/mL) CEP-701 
concentration.  Due to the high viscosity of the warmed (60-65 °C) drug product, a 10 mL 
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positive displacement pipette was used to transfer sample aliquots (7 mL) to 28 (20 mL) glass 
scintillation vials. As the viscous solution cooled, a waxy solid was formed.  The vials were 
filled and capped, with sets of 7 vials placed in stability chambers at 2-8 °C, 25 °C/60% RH,    
30 °C/65% RH, and 40 °C/75% RH.  The filling process was repeated for the uncapped vial 
condition with the cap left off of the vial.  The filling process was repeated for the nitrogen 
overlay vial condition, with the vials being exposed to a nitrogen atmosphere within a glove box 
prior to being capped and stored. 
The samples were removed from the stability chambers at each time point and 
appearance was documented.  At room temperature, the CEP-701 drug product was a solid; so 
the novel active oxygen procedure for a solid excipient, presented in Chapter 5, was followed for 
each stability sample.  Due to the density of the warmed drug product solution being 1.1 g/mL at 
60-65 °C, 7 mL of drug product in the vial equaled 7.7 g.  The drug product samples were 
warmed to 60 °C and 7.7 mL methanol was added to achieve 1 g/mL methanolic solutions.  Due 
to the drug product appearance being yellow in color, color blank samples had to be prepared 
prior to active oxygen analysis (2 mL methanolic sample solution: 4 mL acid solution).  At the  
9-month and 12-month time points, the samples and the corresponding color blanks for all three 
vial conditions held at 40 °C/75% RH, after being placed in the dark for 1 hour, had to be diluted 
(2 mL sample : 4 mL methanol) prior to UV analysis because of their dark yellow appearance.    
The active oxygen levels in the drug product stability samples were measured by the modified 
ASTM E 299-08 method.  Appearance was documented after active oxygen analysis. 
 The CEP-701 drug product methanolic solutions at each time point and in each stability 
condition were diluted and used for the assay and impurity analysis.  Aliquots (240 µL) of the 
CEP-701 drug product methanolic solutions were transferred via a positive displacement pipette 
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to 25 mL volumetric flasks.  The flasks were then filled to volume with methanol to achieve a 
0.25 mg/mL concentration.  Sample aliquots were removed from the flasks and transferred to 
HPLC vials for analysis by the HPLC assay method presented in Table 7.4.  The assay analysis 
of the drug product was conducted with a performance verified Agilent 1100 series High 
Performance Liquid Chromatography (HPLC) system.  The HPLC system included a quaternary 
SL pump, degasser, high performance autosampler SL with thermostat, thermostatted column 
compartment with a 2-valve column switcher, and a DAD SL detector.   
 
Table 7.4: HPLC Method Parameters for Assay Analysis of the CEP-701 Drug Product 
 
Column Alltech, Alltima C18, 150 x 4.6 mm ID, 3 µm packing 
Column Temperature 40 °C 
Autosampler Temperature Ambient 
UV Detection 227 nm 
Injection Volume 10 µL 
Mobile Phase A 0.1% Methanesulfonic Acid (aq) 
Mobile Phase B 100% Acetonitrile 
Run Time 20 min 
Flow Rate 0.8 mL/min 
Gradient 
Time (min) %A %B 
0.0 60 40 
12.0 45 55 
15.0 45 55 
15.1 60 40 
20.0 60 40 
 
 
At the 9-month time point, the uncapped vial sample at 40 °C/75% RH was chosen for analysis 
by LC-MS because the sample had the highest impurity total.  An aliquot was removed from the 
0.25 mg/mL assay solution for the 9 month sample and transferred to an HPLC vial for analysis 
by LC-MS following the method presented in Table 7.5.  LC-MS analysis was conducted with a 





Table 7.5: LC-MS Method Parameters for Impurity Analysis of the CEP-701 Drug Product 
Column Alltech, Alltima C18, 150 x 4.6 mm ID, 3 µm packing 
Column Temperature 40 °C 
Autosampler Temperature Ambient 
Injection Volume 10 µL 
Mobile Phase A 0.1% Formic Acid (aq) 
Mobile Phase B 0.1% Formic Acid in Acetonitrile 
Run Time 20 min 
Flow Rate 0.8 mL/min 
Gradient 
Time (min) %A %B 
0.0 60 40 
12.0 45 55 
15.0 45 55 
15.1 60 40 
20.0 60 40 
Detection 
MS: Electrospray source in positive ion mode and leucine 
enkephalin lockmass.  Compounds were also detected with 
an in-line PDA detector scanning from 210-450 nm. 
 
At the 12-month time point, an additional capped vial sample held at 30 °C/65% RH was 
prepared for analysis by both the modified active oxygen method and the HPLC method.  After 
the sample preparation for HPLC assay analysis, the same solution was used (5 mL) for analysis 
by the active oxygen method.  Additionally, after active oxygen analysis of a separately prepared 
sample, the remaining solution was then diluted (770 µL active oxygen sample: 25 mL 
methanol) for HPLC analysis.  Analysis of the same prepared sample solutions by both methods 
enabled a check to be performed to verify that the methods were both measuring the same 
composition of the starting sample. 
The drug product placebo and both the PEG 1000 and Myrj 52™ individual excipients 
were prepared for stability evaluation.  The same lots of PEG 1000 and Myrj 52™ that were used 
for the CEP-701 drug product were also used for the placebo and excipient stability studies. The 
drug product formulation procedure, shown above, was followed to make the placebo, but the 
CEP-701 drug substance was not included. A 240 g batch was prepared and aliquots (7 mL) of 
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the warmed (60-65 °C) placebo solution were transferred to 28 (20 mL) glass scintillation vials 
using a 10 mL positive displacement pipette.  The vials were capped and placed in stability 
chambers at 5 °C, 25 °C/60% RH, 30 °C/65% RH, and 40 °C/75% RH. 
 PEG 1000 was warmed (60 °C) to a liquid solution and aliquots of 6.9 mL (7.6 g) were 
transferred to 21 (20 mL) glass scintillation vials using a positive displacement pipette.  The 
scintillation vials were capped and sets of 7 vials were placed in stability chambers at 5 °C,       
30 °C/65% RH, and 40 °C/75% RH.  Myrj 52™ (7 g) was transferred to 21 (20 mL) glass 
scintillation vials and each vial was capped.  Sets of 7 scintillation vials, filled with Myrj 52™, 
were placed in stability chambers at 5 °C, 30 °C/65% RH, and 40 °C/75% RH.   
At each time point, the placebo and excipient stability samples were removed from the 
chambers and appearance was documented.  The drug product placebo and excipients were 
solids, so the novel active oxygen procedure for a solid excipient, presented in Chapter 5, was 
followed.  Due to the density of the warmed placebo solution being 1.1 g/mL at 60-65 °C, 7 mL 
of placebo in the vial equaled 7.7 g.  Methanol (7.7 mL) was added to the warmed (60 °C) 
placebo samples to achieve 1 g/mL methanolic solutions.  Methanol was added to the warmed 
(60 °C) PEG 1000 and Myrj 52™ samples (7.6 mL and 7.0 mL, respectively) to obtain 1 g/mL 
methanolic solutions.  Due to the yellow appearance of the Myrj 52™ methanolic solutions, 
color blanks had to be prepared for active oxygen analysis (2 mL Myrj 52™ methanolic solution: 
4 mL acid solution).  The active oxygen levels of the placebo and excipient samples were 
measured by the modified ASTM E 299-08 method.  Appearance was documented after each 






7.3.  Results and Discussion 
The active oxygen, assay, and impurity results for the CEP-701 drug product, with 
corresponding plotted data and appearance, are presented in Table 7.6 – Table 7.8 and      
Figure 7.3 – Figure 7.10.  Summary tables for the percent impurity results for the CEP-701 drug 
product are provided in Table A.1 – Table A.3 in Appendix A.  The LC-MS results for the 
impurity compounds are referenced in Figure B.1 – Figure B.4 in Appendix B.  An example 
HPLC chromatogram for the 9-month stability CEP-701 drug product sample at 40 °C/75% RH 
(uncapped vial condition) is presented in Figure C.1 in Appendix C.  The 25 °C/60% RH 
condition was evaluated as a back-up to the 30 °C/65% RH condition and was only analyzed 
until the 6-month time point, which is indicated by black cells for the 9-month and 12-month 
time points in the following tables and figures. 
 
Table 7.6: Active Oxygen Levels for the CEP-701 Drug Product 
 
 








5 25  30 40  5 25 30 40 5  25  30 40 
Time(mo.) 
0 6.0 6.5 6.0 6.0 6.0 6.5 6.0 6.0 6.0 6.5 6.0 6.0 
1 5.1 6.6 6.2 16.5 4.7 5.9 3.6 5.6 5.3 6.7 6.1 25.9 
2 5.0 7.2 6.4 28.5 4.3 5.6 3.4 6.9 4.8 7.0 6.7 47.3 
3 4.7 7.7 7.4 37.0 4.4 6.3 3.0 23.3 4.7 7.3 7.2 71.4 
6 3.9 12.2 13.4 58.7 3.6 7.0 6.3 55.0 3.9 12.4 12.2 18.8 
9 3.7  19.9 61.1 3.5  4.1 48.3 3.7  15.7 173.7 
12 3.4  26.4 59.4 3.2  18.5 52.1 3.4  22.2 124.3 
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Table 7.7: Assay Levels for the CEP-701 Drug Product 
  Assay (mg/mL) 
Storage 
Condition 
Capped Vial Nitrogen Overlay (w/cap) Uncapped Vial 
Temp. 
(°C) 
5 25 30 40 5 25 30 40 5 25 30 40 
Time 
(mo.) 
0 54.8 53.7 54.8 54.8 54.8 53.7 54.8 54.8 54.8 53.7 54.8 54.8 
1 56.7 53.5 56.3 53.8 56.2 52.9 55.8 55.7 57.3 53.1 56.3 53.4 
2 56.2 51.2 54.2 53.5 55.6 50.1 53.0 51.8 56.5 51.8 54.4 49.6 
3 56.7 49.5 55.3 53.3 56.1 50.1 55.6 54.3 57.5 50.9 55.8 49.1 
6 53.4 51.7 52.8 48.0 53.5 52.0 52.6 48.9 54.8 52.5 52.5 42.0 
9 54.0  51.4 44.3 51.5  52.0 45.9 53.5  51.3 33.1 



























Capped_5 °C Capped_25 °C Capped_30 °C Capped_40 °C
N2 Overlay_5 °C N2 Overlay_25 °C N2 Overlay_30 °C N2 Overlay_40 °C
Uncapped_5 °C Uncapped_25 °C Uncapped_30 °C Uncapped_40 °C
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Table 7.8: Total Percent Impurity Levels for the CEP-701 Drug Product 
  Total Percent Impurity (CEP-701 Related Compounds) 
Storage 
Condition 
Capped Vial Nitrogen Overlay (w/cap) Uncapped Vial 
Temp. 
(°C) 
5 25 30 40 5 25 30 40 5 25 30 40 
Time 
(mo.) 
0 0.31 0.19 0.31 0.31 0.31 0.19 0.31 0.31 0.31 0.19 0.31 0.31 
1 0.32 0.54 0.83 2.02 0.33 0.47 0.65 1.21 0.32 0.52 0.81 2.50 
2 0.37 0.82 1.07 3.56 0.34 0.67 0.78 1.67 0.37 0.78 1.06 4.89 
3 0.37 1.16 1.39 5.23 0.36 0.99 0.87 3.20 0.36 1.01 1.27 8.14 
6 0.43 1.96 2.12 12.21 0.40 1.55 1.55 9.23 0.44 1.79 2.00 21.52 
9 0.47  3.00 17.84 0.44  1.55 14.85 0.48  2.81 39.27 
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Figure 7.10: Appearance of the CEP-701 Drug Product (After Removal from Stability 







The active oxygen stability results and appearance for the drug product placebo are 
presented in Table 7.9 and Figure 7.11. 
 
Table 7.9: Active Oxygen Levels for the Drug Product Placebo 
  Active Oxygen Levels (ppm) 
Sample Placebo 
Storage Condition Capped Vial 
Temp. (°C) 
5 25 30 40 
Time (mo.) 
0 8.13 8.13 8.13 8.13 
1 7.65 8.73 6.90 18.08 
2 7.44 9.88 6.79 0.23 
3 8.01 10.87 7.01 4.40 




















The active oxygen stability results for the drug product excipients, with corresponding 
plotted data and appearance are presented in Table 7.10 and Figure 7.12 – Figure 7.13. 
 
Table 7.10: Active Oxygen Levels for the Drug Product Excipients 
 
  Active Oxygen Levels (ppm) 
Excipient PEG 1000 Myrj 52™ 
Storage Condition  Capped Vial  Capped Vial 
Temp. (°C) 
5 30 40 5 30 40 
Time (mo.) 
0 13.63 13.63 13.63 nd nd nd 
1 13.21 14.44 10.95 nd nd 0.10 
2 12.64 12.39 9.30 nd nd nd 
3 13.56 7.24 8.40 nd nd nd 
6 11.83 6.85 10.71 nd nd nd 
9 11.77 7.41 11.09 nd 0.03 0.00 
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Figure 7.13: Appearance of the Drug Product Excipients (Following Active Oxygen Analysis) 
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Trends were observed following completion of the 12-month stability study for the CEP-
701 drug product.  A plot of the active oxygen results, presented in Figure 7.3, showed that the 
samples held at 40 °C/75% RH for all three vial conditions had the greatest increase in active 
oxygen.  The 9-month data point for the uncapped vial at 40 °C/75% RH had an active oxygen 
level of 173.68 ppm, which confirmed that the result at 6 months was out of trend.  Dilution of 
the 9-month sample at 40 °C/75% RH prior to UV analysis brought the active oxygen level 
within the linear range of the calibration curve.  The reported italicized data point at 6 months for 
the uncapped vial at 40 °C/75% RH (18.8 ppm), in Table 7.6, was likely underestimated because 
dilution prior to UV analysis was not performed.  This data point was removed from the overall 
plot in Figure 7.3 containing active oxygen levels at 40 °C/75% RH for that reason. The samples 
held at 25 °C/60% RH and 30 °C/65% RH for all three vial conditions, presented in Figure 7.4 
and Figure 7.5, had intermediate levels of active oxygen between the levels at 40 °C/75% RH 
and 5 °C (Figure 7.6).  The active oxygen levels for the capped and uncapped vials at 30 
°C/65% RH increased between 3 and 12 months on stability, while the levels for the nitrogen 
overlay vials increased between 9 and 12 months.  The active oxygen levels for the samples held 
at 5 °C for all three vial conditions, presented in Figure 7.6, were the lowest in magnitude and 
remained stable.    The nitrogen overlay vial condition had the lowest active oxygen level for 
each temperature condition.  The total percent impurity levels for the CEP-701-related impurity 
compounds, presented in Table 7.8 and Figure 7.9, followed the same trends as the active 
oxygen levels.  The samples held at 40 °C/75% RH for all three vial conditions had the highest 
total impurity levels, followed by the 25 °C/60% RH and 30 °C/65% RH results, and then the     
5 °C results, which were stable.  As the total impurity levels increased, the assay levels decreased 
accordingly as displayed in Table 7.7 and Figure 7.8.  
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 The impurity peaks in the CEP-701 stability samples were of large magnitude at the       
9-month time point, which enabled LC-MS analysis to be performed to verify the identity of the 
impurities.  The ultimate goal was to verify the peroxy-related CEP-701 impurities, in        
Figure 7.1, in order to see if the modified active oxygen method successfully quantified the 
peroxy impurities.  The peroxy-related CEP-701 impurity compounds are diastereomers labeled 
as compounds 2 and 3.  The additional oxidative degradants for CEP-701 are hydroxy 
compounds 4 and 5 and impurity compound 6.   
The LC-MS results for the 9-month, uncapped vial sample, at 40 °C/75%RH are 
presented in Figure B.1 – Figure B.5 in Appendix B and show identification of impurity 
compounds 2-9.  The extracted ion chromatograms (EIC) were obtained for the known mass of 
each CEP-701 oxidative impurity along with the UV diode array chromatogram.  As shown in 
Figure B.1 in Appendix B, strong signals were present for CEP-701 (1) (tR = 9.23 min) and 
compound 6 (tR = 13.42 min).  The peroxy compounds 2 and 3 had quantifiable signals at tR = 
5.86 min and tR = 8.16 min and the hydroxy compounds 4 and 5 had signals at tR = 5.04 min and 
tR = 6.95 min.   
In addition to the known CEP-701 oxidative degradants, three additional impurity peaks 
were prevalent and grew over time in the HPLC assay analysis.  The impurity peaks had 
retention times equal to 7.80 min, 10.08 min, and 12.55 min in the LC-MS chromatograms.  The 
extracted mass spectrum for the peak with tR = 7.80 min, shown in Figure B.2 in Appendix B, 
produced a major fragment ion [M+H]
+
 = 470, which equaled m/z 469.  An extracted ion 
chromatogram, presented in Figure B.1 in Appendix B, was obtained for [M+H]
+
 = 470 and two 
peaks were found at tR = 7.82 min and 10.07 min.  The extracted mass spectrum for the peak 





 = 466, which equaled m/z 465.  An extracted ion chromatogram, presented in Figure 
B.4 in Appendix B, was obtained for [M+H]
+
 = 466 and a peak was found at tR = 12.54 min.   
To identify the structures of the unknown impurities at retention times 7.80 min, 10.08 
min, and 12.55 min, formaldehyde and acetaldehyde addition were considered.  Formaldehyde 
and acetaldehyde are prevalent in PEG 1000 and can interact with the nitrogen of the 2-
pyrrolidone ring in the CEP-701 structure.
6
  Formaldehyde and acetaldehyde addition to CEP-
701 would produce the structures presented in Figure 7.2 and are identified as compound 7 (m/z 
469), compound 8 (m/z 483), and compound 9 (m/z 469) respectively.  Compound 7 is 
formaldehyde addition to the nitrogen of the 2-pyrrolidone ring and was therefore identified as 
the unknown peak at tR = 7.80 min and the enol form, compound 9 (formaldehyde addition to the 
oxygen), was identified as the unknown peak at tR = 10.08 min.  Compound 8 was identified as 
the unknown peak at tR = 12.55 min, with [M-H2O+H]
+
 = 466 as the major fragment identified 
for the compound.  A corrected mass spectrum is presented in Figure B.3 in Appendix B, with 
the fragments relabeled with the knowledge of [M+H]
+
 = 484. 
The relative retention times for the peaks in the LC-MS chromatograms were compared 
to those in the HPLC chromatograms to properly identify and track the CEP-701 impurities.  The 
9-month HPLC chromatogram for the uncapped vial at 40 °C/75% RH is presented in        
Figure C.1, in Appendix C, with the CEP-701 impurity peaks properly labeled.  To correlate the 
active oxygen levels in µg or ppm to the percent impurity levels, the active oxygen levels were 
converted to assay terms (mg/mL).  The following conversion equation was used: 
[(Active oxygen level (µg) x F) / (5 mL x 1000 µL/1 mL)] x 100% = % Impurity 
                                    Initial Diluted Assay Claim (mg/mL) 
where F is the active oxygen conversion factor for the  CEP-701 peroxy impurities 2 and 3.  The 
peroxy compounds 2 and 3 have a molecular weight of 471.14 g/mol and therefore a conversion 
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factor, F, of 29.44625 (see the equation for F calculation in Chapter 2).  The active oxygen levels 
for the capped vials at 40 °C/75% RH and 30 °C/65% RH were converted to peroxy percent 
impurity values. The capped vial condition was used so comparisons could be made to the 
placebo stability study that also used the capped vial condition.  The active oxygen results for the 
nitrogen overlay and uncapped vial conditions at 30 °C/65% RH and 40 °C/75% RH were also 
converted to peroxy percent impurity values and are presented in Figures D.1- D.4 in Appendix 
D. The peroxy percent impurity values calculated by the active oxygen method (dotted line) were 
plotted against the assay percent impurity levels of the peroxy, hydroxy, formaldehyde, 
acetaldehyde, and compound 6 related CEP-701 compounds in Figure 7.14 and Figure 7.15.   
 
Figure 7.14: Comparison of CEP-701-Related Active Oxygen (Peroxy), Formaldehyde, 
      Acetaldehyde, Peroxy, Hydroxy, and Compound 6 Impurities in the Capped  
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Figure 7.15: Comparison of CEP-701-Related Active Oxygen (Peroxy), Formaldehyde, 
      Acetaldehyde, Peroxy, Hydroxy, and Compound 6 Impurities in the Capped   
      Vial at 30 °C/65% RH Sample 
 
The peroxy compounds 2 and 3 were short-lived in the HPLC analyzed stability samples 
and were converted to the hydroxy compounds 4 and 5, and then to compound 6. The instability 
of the peroxy compounds can be attributed to the presence of silica gel in the column, which can 
have surface interaction and catalyze peroxide decomposition.
7,8
  The catalyzed decomposition 
and conversion of the peroxy and hydroxy compounds by the conditions of the HPLC method 
explained why compound 6 was the largest impurity peak detected by the assay method.  The 
comparison between the percent impurity levels, in Figure 7.15, for the 30 °C/65% RH 
condition showed that the active oxygen method successfully quantified the peroxy impurities 
and that the levels coincided with the HPLC assay impurity totals for compound 6.  The 
coinciding rates showed that the formation rate of the CEP-701 peroxy impurity was equal to the 
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that the assay value for the sample after active oxygen analysis was 51.38 mg/mL (3.62% 
impurity for compound 6), which corresponded to the actual assay determined value of        
50.29 mg/mL (3.62% impurity for compound 6).    Likewise, the active oxygen level for the 
sample prepared for HPLC analysis had an absorbance of 0.0236 AU at the 410 nm wavelength, 
which corresponded to the actual active oxygen determined absorbance value of 0.0174 AU.  
The comparison between the impurity levels in Figure 7.14, for the 40 °C/75% RH condition, 
showed that the active oxygen levels coincided with the HPLC assay impurity totals for 
compound 6 within the first 3 months.  In the first three months at the accelerated temperature 
condition, the formation rate of the CEP-701 peroxy impurity was equal to the decomposition 
rate to compound 6 and between 3 and 12 months, the peroxy decomposition was faster than the 
rate of formation.  The continued formation rate of compound 6 was present as the active oxygen 
calculated CEP-701 peroxy levels reached steady state. The modified ASTM E 299-08 method 
was therefore more sensitive than the HPLC assay method in detection of the peroxy levels in the 
CEP-701 stability samples because the results related directly to the amount of peroxy present.   
The individual excipient stability study showed some trends were evident throughout the 
9 months of the study.  The 9-month data for the excipient stability study at 30°C/65%RH and 40 
°C/75% RH, presented in Figure 7.12, showed that over time the active oxygen levels for PEG 
1000 decreased to steady-state levels and that the levels remained non-detectable for Myrj 52™.  
The active oxygen-forming moieties in PEG 1000 produced the initial levels, but over time 
degraded or converted into PEG impurities whose detection was not specific to the active oxygen 
method.  PEG 1000 was therefore shown to be the main contributor of the active oxygen levels 
present in the placebo. 
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As PEG 1000 degraded on stability, PEG impurities and related radicals were formed.  
The increased presence of the formaldehyde impurity from PEG caused the CEP-701 degradants 
related to formaldehyde addition to form.  The comparison between the formation of CEP-701 
formaldehyde compounds 7 and 9 and the rate of active oxygen formation in the drug product 
can be viewed in Figure 7.14 and Figure 7.15.  The active oxygen levels for the CEP-701 drug 
product at 40 °C/75% RH are plotted against the active oxygen levels for the placebo in Figure 
7.16.  The active oxygen levels observed in the placebo at 40 °C/75% RH within the first 6 
months correlated with the peroxy impurity and active oxygen results observed for the CEP-701 
drug product.  The rates of active oxygen formation within the first month for the placebo (9.95 
ppm/month) and drug product (10.50 ppm/month) were similar.  After the first month, the 
excipients in the placebo decreased in active oxygen (6.84 ppm/month) and produced more 
radicals.  The radical initiated oxidative degradation of the drug product consequently increased 
to the same rate (7.48 ppm active oxygen/month).  
 
Figure 7.16: Active Oxygen Levels for the CEP-701 Drug Product and Placebo at                   
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7.4.  Conclusions 
 The oxidative degradation of the CEP-701 drug product was successfully quantified 
orthogonally by the modified ASTM E 299-08 method and the HPLC assay method.  The 
modified active oxygen method was able to quantify the total levels of active oxygen as well as 
the primary peroxy impurity produced in the drug product.  The HPLC assay method confirmed 
the accuracy of the results produced by the modified active oxygen method.  The modified 
ASTM E 299-08 method was suitable for sensitive detection of active oxygen levels in 
excipients, placebos, and drug products without derivatization or manipulation of the sample.  
The modified active oxygen method showed that it can be used as a preliminary test for 
screening new formulations, to predict the possible reaction mechanisms that can occur between 
the excipient’s reactive impurities and the drug substance, before performing a full stability 
study.  Being proactive in screening an excipient in formulation development can necessitate the 
change to a different excipient or inclusion of an antioxidant early in the process, which saves 
valuable development time and enhances drug substance and excipient compatibility. 
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CHAPTER 8.  Final Conclusions and Future Considerations 
 
 The modifications made to the ASTM E 299-08 method described in this thesis reduced 
the procedural steps of the 1966 original method, eliminated the need for a special absorption 
cell without sacrificing sensitivity or reproducibility, and increased the lower magnitude range of 
the calibration curves.  The method successfully quantified spiked amounts of hydrogen peroxide 
(HOOH), tert-butyl hydroperoxide (ROOH), and dibenzoyl peroxide (ROOR), thus 
demonstrating the method’s non-discriminatory response for peroxide detection.  The modified 
ASTM E 299-08 method was advantageous over other techniques because it was not specific to 
just one form of a peroxide compound and could also measure total active oxygen as well. 
 The versatility in the types of peroxide detected by this method enabled complex 
pharmaceutical excipients to be evaluated.  The modified ASTM E 299-08 method detected 
active oxygen levels in liquid excipients, in the range of 0.04 ppm – 122.06 ppm, from varying 
chemical classes including water-insoluble, triglyceride, and surfactant.  A novel procedure was 
implemented in the sample preparation of solid excipients to enable a comparative analysis to 
liquid excipients.  The modified method detected active oxygen levels in solid excipients, in the 
range of 0.38 ppm – 156.85 ppm, from the carrier types: povidone, polyethylene glycol, and 
poloxamer.  The incorporation of the above types of excipients in formulations is growing to 
combat the increase in poorly water-soluble API in the development pipeline, which makes 
knowledge of the active oxygen content important. 
 The polyethylene glycol (PEG) class of excipients was further studied by the modified 
ASTM E 299-08 method since it had molecular weight grades that are liquid (PEG 400) and 
solid (PEG 4000).  The impact of the physical composition of the PEG compounds on the rate of 
active oxygen formation was also evaluated.  The observation was that the PEG compounds 
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susceptible to autoxidation experienced a steady-state active oxygen level before first-order 
decay at the accelerated 40 °C/75% RH condition.  PEG 400, a liquid, had more contact with 
oxygen both internally and externally than PEG 4000, a solid, which had only external contact.  





.  PEG 4000 was a higher molecular weight compound and a solid so therefore was 
not susceptible to autoxidation under the conditions studied.   
 The PEG 1000 compound was formulated in a drug product to evaluate the impact that an 
excipient, which was susceptible to autoxidation and contained active oxygen components, had 
on the drug substance stability.  A model drug product was chosen, which contained CEP-701 
API and PEG 1000 as one of the excipients.  The drug product, placebo, and individual 
excipients were placed on stability at a range of storage and accelerated temperature conditions 
within different vial conditions.  The active oxygen levels were evaluated by the modified 
ASTM E 299-08 method and an orthogonal HPLC assay method was used to evaluate the assay 
and impurity levels.  The modified ASTM E 299-08 method successfully quantified the CEP-701 
peroxy-related impurity and the levels matched those obtained by the HPLC assay method for 
the final oxidative impurity product.   
The modified active oxygen method is suitable for trace level detection of active oxygen 
in excipients, placebos, and drug products without derivatization or manipulation of the sample.  
The modified active oxygen method can be used as a preliminary screen for new formulations to 
predict the potential degradation reactions that can occur.  In the case of the demonstrated model 
drug product, a targeted therapy drug for AML where patients only have a 26% percent five-year 
survival rate, screening the formulation by the modified active oxygen method would have been 
imperative in the development phase to eliminate downstream drug product instability.  The 
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modified ASTM E 299-08 method would have shown that an antioxidant was needed from the 
onset without direct knowledge of the impurity peroxide, which would have saved development 
time and enhanced drug product stability, potentially enabling a life-improving drug to reach the 
market more quickly that would otherwise have not been the case.   
The novel modified ASTM E 299-08 method developed is a sensitive, versatile, reliable, 
and reproducible method that has significant application in the pharmaceutical industry.  To 
further explore the application of the modified ASTM E 299-08 method, additional drug product 
formulations should be evaluated.  The drug product formulations should consist of various 
compositions common to pharmaceuticals such as liquids, suspensions, and tablets.  The drug 
products should be placed on stability and evaluated for active oxygen and potential peroxide 
impurities by the modified ASTM E 299-08 method.  The incorporation of antioxidants in the 
drug products should also be explored and the active oxygen levels quantified, to show the 
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Figure B.1: Extracted Ion Chromatograms and Diode Array Chromatogram for the CEP-701 
                       Drug Product Impurity Compounds (Sample: Uncapped Vial Held for 9 Months  












Figure B.3: Mass Spectrum for the CEP-701 Impurity Peak with tR = 12.55 min  













Figure B.4: Extracted Ion Chromatogram and Diode Array Chromatogram for the CEP-701 
  Impurity Peak with [M+H]
+







Figure C.1: HPLC Chromatogram for the CEP-701 Drug Product Stability Sample: Uncapped 

















Figure D.1: Comparison of CEP-701-Related Active Oxygen (Peroxy), Formaldehyde, 
      Acetaldehyde, Peroxy, Hydroxy, and Compound 6 Impurities in the Uncapped 




Figure D.2: Comparison of CEP-701-Related Active Oxygen (Peroxy), Formaldehyde, 
      Acetaldehyde, Peroxy, Hydroxy, and Compound 6 Impurities in the Uncapped 

















Active Oxygen (peroxy) Formaldehyde Acetaldehyde















Active Oxygen (peroxy) Formaldehyde Acetaldehyde





Figure D.3: Comparison of CEP-701-Related Active Oxygen (Peroxy), Formaldehyde, 
      Acetaldehyde, Peroxy, Hydroxy, and Compound 6 Impurities in the Nitrogen  




Figure D.4: Comparison of CEP-701-Related Active Oxygen (Peroxy), Formaldehyde, 
      Acetaldehyde, Peroxy, Hydroxy, and Compound 6 Impurities in the Nitrogen  




















Active Oxygen (peroxy) Formaldehyde Acetaldehyde















Active Oxygen (peroxy) Formaldehyde Acetaldehyde
Peroxy Hydroxy Compound 6
